Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
暂无分享,去创建一个
M. Gore | P. Nathan | P. Lorigan | M. Marples | A. Marshall | J. Dunn | M. Harries | M. Middleton | N. Davidson | P. Corrie | S. Danson | S. Nicholson | R. Board | S. Houston | C. Kelly | E. Marshall | Satish B. Kumar | A. Waterston | J. Nobes | G. Young